Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.5B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Tesla
TSLA
|
+$951M |
| 4 |
Johnson & Johnson
JNJ
|
+$750M |
| 5 |
UnitedHealth
UNH
|
+$703M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$913M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$257M |
| 3 |
NVIDIA
NVDA
|
+$225M |
| 4 |
Vertiv
VRT
|
+$164M |
| 5 |
JPMorgan Chase
JPM
|
+$161M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.48% |
| 2 | Healthcare | 7.36% |
| 3 | Financials | 6.5% |
| 4 | Consumer Discretionary | 5.35% |
| 5 | Industrials | 3.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
THRX
4426
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $44.3K | ﹤0.01% |
8,904
+3,844
| +76% | +$22.5K |
|
4427
Porch Group
PRCH
$1.64B
| $43.9K | ﹤0.01% |
23,367
+16,408
| +236% | +$29K |
|
|
KRON
4428
DELISTED
Kronos Bio
KRON
| $43.8K | ﹤0.01% |
27,053
+9,200
| +52% | +$21.2K |
|
4429
Rocky Brands
RCKY
$366M
| $43.7K | ﹤0.01% |
1,850
+1,534
| +485% | +$35.5K |
|
|
DNMR
4430
DELISTED
Danimer Scientific, Inc.
DNMR
| $43.6K | ﹤0.01% |
608
+509
| +514% | +$48.1K |
|
|
FRGE
4431
DELISTED
Forge Global Holdings
FRGE
| $43.3K | ﹤0.01% |
1,667
| – | – |
|
|
NGMS
4432
DELISTED
NeoGames S.A. Ordinary Shares
NGMS
| $43.2K | ﹤0.01% |
3,545
+2,273
| +179% | +$34.2K |
|
|
NCTY
4433
The9 Ltd
NCTY
$68.1M
| $43.1K | ﹤0.01% |
7,600
| – | – |
|
4434
Cartesian Therapeutics
RNAC
$229M
| $42.9K | ﹤0.01% |
1,267
-38
| -3% | -$1.62K |
|
4435
HighPeak Energy
HPK
$903M
| $42.9K | ﹤0.01% |
1,876
+1,590
| +556% | +$35.8K |
|
4436
Dakota Gold
DC
$608M
| $42.8K | ﹤0.01% |
14,027
+11,848
| +544% | +$40.4K |
|
4437
Lexicon Pharmaceuticals
LXRX
$1.03B
| $42.7K | ﹤0.01% |
22,360
+18,829
| +533% | +$40.1K |
|
4438
Culp Inc
CULP
$44.1M
| $42.4K | ﹤0.01% |
9,228
-249
| -3% | -$1.18K |
|
|
SVM
4439
Silvercorp Metals
SVM
$2.07B
| $42.3K | ﹤0.01% |
14,300
+3,200
| +29% | +$8.67K |
|
|
JNCE
4440
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $42.3K | ﹤0.01% |
38,071
+9,528
| +33% | +$13.6K |
|
4441
Silicom
SILC
$229M
| $42.1K | ﹤0.01% |
1,000
| – | – |
|
4442
State Street SPDR S&P Kensho Smart Mobility ETF
HAIL
$18.9M
| $42.1K | ﹤0.01% |
1,430
| – | – |
|
|
EGIO
4443
DELISTED
Edgio, Inc. Common Stock
EGIO
| $41.7K | ﹤0.01% |
922
+776
| +532% | +$59.8K |
|
|
VLDR
4444
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
| $41.4K | ﹤0.01% |
56,066
+46,447
| +483% | +$43.9K |
|
4445
NACCO Industries
NC
$357M
| $41.4K | ﹤0.01% |
1,089
+917
| +533% | +$43.1K |
|
4446
CALL
DuPont de Nemours
DD
$18.5B
| $41.2K | ﹤0.01% |
+478
| New | +$38.2K |
|
4447
iShares Asia 50 ETF
AIA
$4.6B
| $41.1K | ﹤0.01% |
725
| – | – |
|
4448
Outdoor Holding Co
POWW
$249M
| $41.1K | ﹤0.01% |
23,754
+20,049
| +541% | +$50.6K |
|
4449
iShares MSCI EAFE Value ETF
EFV
$28.8B
| $40.8K | ﹤0.01% |
+890
| New | +$38.6K |
|
4450
Korro Bio
KRRO
$150M
| $40.8K | ﹤0.01% |
212
-19
| -8% | -$1.96K |
|
Similar funds
Barclays's Q4 2022 Portfolio in Review
As of Q4 2022, Barclays held 5,646 positions worth $223B, up 144% from $91.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $128B of net new capital in Q4 2022, opening 798 new positions and adding to 2,634 existing holdings. Its largest new stake was Seadrill: 1,546,558 shares worth $50.5M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $257M trimmed.
- Barclays's largest Q4 2022 buy was Seadrill: 1,546,558 shares worth $50.5M.
- Barclays added most to Microsoft in Q4 2022, an estimated $2.5B increase.
- Barclays's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $257M.
- Barclays fully exited Citrix Systems Inc in Q4 2022, selling an estimated $913M.
- Barclays's ten largest holdings make up 41% of its $223B portfolio in Q4 2022.
- Barclays opened 798 new positions and closed 385 in Q4 2022.
- Barclays's portfolio value rose 144% quarter-over-quarter to $223B.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.